272 related articles for article (PubMed ID: 16691061)
1. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
[TBL] [Abstract][Full Text] [Related]
4. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study.
Schwartz JL; Mauck C; Lai JJ; Creinin MD; Brache V; Ballagh SA; Weiner DH; Hillier SL; Fichorova RN; Callahan M
Contraception; 2006 Aug; 74(2):133-40. PubMed ID: 16860051
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Giguere JF; Domingo MC; Piret J; Tsague L; Zekeng L; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2009 Nov; 80(5):484-92. PubMed ID: 19835725
[TBL] [Abstract][Full Text] [Related]
6. Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men.
Jespers V; Buvé A; Van Damme L
Sex Transm Dis; 2007 Jul; 34(7):519-22. PubMed ID: 17297382
[TBL] [Abstract][Full Text] [Related]
7. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days.
Doh AS; Ngoh N; Roddy R; Lai JJ; Linton K; Mauck C
Contraception; 2007 Sep; 76(3):245-9. PubMed ID: 17707724
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of Carraguard vaginal gel use among Thai couples.
Whitehead SJ; Kilmarx PH; Blanchard K; Manopaiboon C; Chaikummao S; Friedland B; Achalapong J; Wankrairoj M; Mock P; Thanprasertsuk S; Tappero JW
AIDS; 2006 Nov; 20(17):2141-8. PubMed ID: 17086053
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
[TBL] [Abstract][Full Text] [Related]
11. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.
Van Damme L; Govinden R; Mirembe FM; Guédou F; Solomon S; Becker ML; Pradeep BS; Krishnan AK; Alary M; Pande B; Ramjee G; Deese J; Crucitti T; Taylor D;
N Engl J Med; 2008 Jul; 359(5):463-72. PubMed ID: 18669425
[TBL] [Abstract][Full Text] [Related]
12. Fourteen-day safety and acceptability study of the universal placebo gel.
Schwartz JL; Ballagh SA; Kwok C; Mauck CK; Weiner DH; Rencher WF; Callahan MM
Contraception; 2007 Feb; 75(2):136-41. PubMed ID: 17241844
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners.
Trottier S; Omar RF; Désormeaux A; Drouin J; Gagnon MT; Vezina F; Guilbert E; Mâsse B; Bergeron MG
Contraception; 2007 Aug; 76(2):117-25. PubMed ID: 17656181
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe.
van der Straten A; Napierala S; Cheng H; Mauck C; Depineres T; Dhlakama P; Thompson M; Chipato T; Hammond N; Padian N
Contraception; 2007 Nov; 76(5):389-99. PubMed ID: 17963865
[TBL] [Abstract][Full Text] [Related]
15. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Malonza IM; Mirembe F; Nakabiito C; Odusoga LO; Osinupebi OA; Hazari K; Chitlange S; Ali MM; Callahan M; Van Damme L
AIDS; 2005 Dec; 19(18):2157-63. PubMed ID: 16284466
[TBL] [Abstract][Full Text] [Related]
16. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
[TBL] [Abstract][Full Text] [Related]
17. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India--Phase I study.
Joglekar NS; Joshi SN; Navlakha SN; Katti UR; Mehendale SM
Indian J Med Res; 2006 Apr; 123(4):547-52. PubMed ID: 16783046
[TBL] [Abstract][Full Text] [Related]
18. Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly.
von Mollendorf CE; Van Damme L; Moyes JA; Rees VH; Callahan MM; Mauck CK; Puren AJ; Tweedy K; Taylor D
Contraception; 2010 Mar; 81(3):232-9. PubMed ID: 20159180
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.
Joglekar N; Joshi S; Kakde M; Fang G; Cianciola M; Reynolds S; Mehendale S;
AIDS Care; 2007 Jul; 19(6):817-21. PubMed ID: 17573603
[TBL] [Abstract][Full Text] [Related]
20. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews.
Turner AN; De Kock AE; Meehan-Ritter A; Blanchard K; Sebola MH; Hoosen AA; Coetzee N; Ellertson C
J Clin Epidemiol; 2009 Jul; 62(7):759-65. PubMed ID: 19013762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
